Investigación e Informes
Informes técnicos, estudios y datos de mercado
Investigación e Informes
2 sept 2026•1 min de lectura
Eli Lilly and Novo Nordisk Lead AI Platform Citations Among Pharma Companies
Eli Lilly and Novo Nordisk top AI platform citations, surpassing Merck, AbbVie, J&J and Pfizer, driven by GLP‑1 therapy interest.
Investigación e Informes
2 sept 2026•1 min de lectura
KPA Calls Pharmacies to Join Braille Prescription Software Pilot
The Korean Pharmaceutical Association seeks pharmacies in Seoul, Gyeonggi and Incheon to test PM+20 billing software integrated with a Braille printer, improving medication safety for visually impaired patients.
Investigación e Informes
1 sept 2026•1 min de lectura
Korean Pharmaceutical Association Launches AI‑Driven Public Outreach and Pharmacy Support Platforms
The Korean Pharmaceutical Association announced the launch of 'PharmSNS' for pharmacist‑public communication and the formation of a working group to develop AI tools for pharmacy workflow efficiency.
Investigación e Informes
1 sept 2026•1 min de lectura
PCMO and BaielT Sign MOU to Advance mRNA Therapeutics Development
PCMO and biotech venture BaielT have signed an MOU to collaborate on the full development cycle of mRNA medicines, from process development to GMP production and commercialization.
Investigación e Informes
1 sept 2026•1 min de lectura
Men Detect Cancer Later Than Women, Study Shows
U.S. NCI analysis of 2.4 million cancer patients (2015‑2022) finds men are more often diagnosed after the disease has spread, contributing to higher male cancer mortality.
Investigación e Informes
1 sept 2026•1 min de lectura
AI Chatbots Mirror Social Bias Toward Mental Illness and HIV Patients, Study Finds
A study by Beijing University researchers published in Nature Health shows AI chatbots like ChatGPT, Claude, and DeepSeek reflect societal prejudice against people with mental disorders and HIV.
Investigación e Informes
1 sept 2026•1 min de lectura
Roche halts development of two Huntington’s disease drug candidates
Roche announced it will discontinue the Phase 2 trial of tominersen and the Phase 1 trial of RG6496, ending its Huntington’s disease program and disappointing patients.
Investigación e Informes
1 sept 2026•1 min de lectura
Ipsen's Dysport Meets Primary Endpoints in Phase 3 Trials for Episodic and Chronic Migraine Prevention
Ipsen reported that its botulinum toxin Dysport achieved primary goals in two Phase 3 studies for preventing episodic and chronic migraine, marking the first positive result in episodic migraine for a botulinum product.
Investigación e Informes
1 sept 2026•1 min de lectura
Sinetrol Complex Extract: Citrus Polyphenols for Fat Reduction
Sinetrol, a blend of grapefruit, orange and guarana extracts, is used as a functional ingredient for body‑fat reduction, featuring naringin and hesperidin as key actives.
Investigación e Informes
1 sept 2026•1 min de lectura
Lung Cancer 5‑Year Survival in Korea Jumps to 42.5% Amid EGFR‑TKI Advances
Korea’s 5‑year lung cancer survival rate rose to 42.5% in 2023, driven by targeted therapies and the 10‑year anniversary of third‑gen EGFR‑TKI Tagrisso.
Investigación e Informes
1 sept 2026•1 min de lectura
Fatty Liver May Accelerate Liver Metastasis in Colorectal Cancer, Study Finds
Belgian researchers reported that fatty liver creates an environment that promotes liver invasion by colorectal cancer cells, worsening prognosis, as published in Nature.
Investigación e Informes
1 sept 2026•1 min de lectura
Bariatric Surgery Increases Alcohol Absorption, Raising Dependence Risk, Study Finds
Research from NTNU shows patients after gastric bypass or sleeve gastrectomy absorb alcohol faster, leading to higher intoxication and dependence risk.